Anti-hair loss composition and preparation method thereof

Abstract

The invention discloses a preparation method of an anti-hair loss composition. A production raw material formula comprises a DNA sodium-cacumen biotae extract composite solution and a buffer solution system, the DNA sodium-cacumen biotae extract composite solution is prepared from the following components in parts by mole: 0.06 to 0.5 part of DNA sodium in terms of deoxyribonucleic acid sodium salt and 80 parts of cacumen biotae extract mother liquor in terms of quercetin. The DNA sodium anti-hair loss preparation has the advantage that the hair growth effect of the existing DNA sodium anti-hair loss preparation can be obviously improved.

Description

Technical Field

[0001] The present invention relates to the field of biomedical technologies, and in particular to a production technology of an anti - hair - loss composition. Background Art

[0002] With the changes in people's living and eating habits and the increase in stress, hair loss has become a very common problem and is getting younger, becoming one of the reasons for the anxiety of modern young people.

[0003] Hair loss refers to the symptoms of at least 100 hairs falling out every day, a decrease in the hair in the anagen phase, and an increase in the hair in the catagen and telogen phases. As hair loss progresses, the telogen hair rate increases rapidly, and the anagen hair rate decreases correspondingly. Hair loss generally includes hereditary androgenetic alopecia (baldness), alopecia areata, tinea capitis caused by fungal infection, telogen effluvium, trichotillomania, hair growth disorders, etc. The most common hair loss includes baldness (male hair loss), female hair loss, alopecia areata, and telogen hair loss, etc.

[0004] Modern pathological research shows that the causes of hair loss include endocrine disorders, long - term mental stress, malnutrition, long - term hair dyeing and perming, etc.

[0005] Currently, common hair - loss treatment products are finasteride and minoxidil. Finasteride is a drug for treating male hair loss, which inhibits hair loss by inhibiting the mechanism of 5α - reductase. 5α - reductase is an enzyme that converts male hormones into the hair - loss - inducing factor dihydrotestosterone (DHT). Minoxidil inhibits hair loss by increasing blood flow to the scalp. However, these therapies are often reported to have some side effects, and their treatment effects are temporary and limited. Hair loss is caused by a combination of multiple factors rather than any single factor, and the solution of some factors cannot completely cure it.

[0006] Sodium DNA (polydeoxyribonucleotide) was reported to have the functions of anti - hair - loss and promoting hair growth in the patent application of CN112041329A. Its principle is to increase the secretion of β - catenin by promoting the activation of the signal transduction pathway of the hair - growth signal system and cell activation, and to increase the growth of keratinocytes, fibroblasts, and dermal papilla cells, which are the hair - forming cells, to prevent hair loss and promote hair growth. However, in the experimental process, we found that its anti - hair - loss effect is relatively limited. Therefore, to improve the use effect of the sodium DNA anti - hair - loss preparation, the present invention provides an anti - hair - loss composition and its preparation method. Summary of the Invention

[0007] To improve the anti - hair - loss effect of the sodium DNA anti - hair - loss preparation, the present invention provides an anti - hair - loss composition and its preparation method.

[0008] The technical solution adopted by the present invention is: a preparation method of an anti-hair loss composition, and the production raw material formula includes a DNA sodium-platycladus orientalis extract composite solution and a buffer system; the DNA sodium-platycladus orientalis extract composite solution includes the following components in molar ratio: 0.06-0.5 parts of DNA sodium calculated as deoxyribonucleic acid sodium salt, and 80 parts of a platycladus orientalis extract mother liquor calculated as quercetin.

[0009] As a further improvement of the present invention, the platycladus orientalis extract mother liquor is obtained by dissolving the platycladus orientalis extract with ethanol. More preferably, the concentration of the platycladus orientalis extract in the platycladus orientalis extract mother liquor calculated as quercetin is 7000-9000 μmol / L.

[0010] As a further improvement of the present invention, the preparation raw materials of the buffer system include the following components in mass ratio: 1 part of glycine, 0.5-1.5 parts of glutamine, 2-4 parts of pentanediol, 0.3-0.8 parts of arginine hydrochloride, and 0.05-0.2 parts of sodium hyaluronate. More preferably, the concentration of DNA sodium calculated as deoxyribonucleic acid sodium salt in the anti-hair loss composition is 60-500 nmol / L.

[0011] More preferably, the platycladus orientalis extract mother liquor is prepared as follows: dissolve the platycladus orientalis extract with absolute ethanol, centrifuge at 1200-1800 g for more than 30 s, take the supernatant, and obtain the product after sterilization filtration.

[0012] The preparation method of the anti-hair loss composition of the present invention can be specifically implemented according to the following steps:

[0013] S1. Weigh the raw materials according to the production raw material formula;

[0014] S2. Dilute the platycladus orientalis extract mother liquor with purified water; add the DNA sodium to the aqueous solution of the diluted platycladus orientalis extract mother liquor and mix well; then add the buffer system according to the process-set concentration and mix well.

[0015] The present invention also discloses an anti-hair loss composition, which is prepared by the preparation method of the anti-hair loss composition of the present invention.

[0016] The present invention also discloses an external preparation for preventing hair loss, which is characterized in that the composition includes the anti-hair loss composition of the present invention. It is easy to understand that the external preparation for preventing hair loss can be common external ointments, cosmetics, skin sprays, etc.

[0017] The beneficial effect of the present invention is: it can significantly improve the anti-hair loss or hair growth effect of the existing DNA sodium anti-hair loss preparation. Description of the Drawings

[0018] Figure 1It is a graph showing the comparison results of hair coverage in animal experiments of the specific implementation method.

[0019] Figure 2 It is a graph showing the comparison results of hair scores in animal experiments of the specific implementation method.

[0020] Figure 3 It is a comparison graph of the treatment effects of the remaining * patients in the experimental drug A treatment group for subjects in the specific implementation method.

[0021] Figure 4 It is a comparison graph of the treatment effects of patient Zhang ** in the experimental drug B treatment group for subjects in the specific implementation method.

[0022] Figure 5 It is a comparison graph of the treatment effects of patient Liu ** in the experimental drug C treatment group for subjects in the specific implementation method.

[0023] Figure 6 It is a comparison graph of the treatment effects of patient Feng * in the experimental drug D treatment group for subjects in the specific implementation method.

[0024] Figure 7 It is a comparison graph of the treatment effects of patient Lin ** in the experimental drug C treatment group for subjects in the specific implementation method. Specific implementation method

[0025] The present invention will be further described below in conjunction with embodiments.

[0026] Sources of main raw and auxiliary materials in the specific implementation method:

[0027]

[0028] Example 1:

[0029] Prepare the anti - hair - loss composition according to the following method:

[0030] (1) Weigh the raw materials according to the following production raw material formula in molar ratio: 0.0625 parts of DNA sodium calculated as deoxyribonucleic acid sodium salt, and 80 parts of the mother liquor of Platycladus orientalis extract calculated as quercetin;

[0031] Among them, the mother liquor of Platycladus orientalis extract is prepared according to the following method: Dissolve Platycladus orientalis extract (C 槲皮素 is 3.2%) with absolute ethanol for 40 min, centrifuge at 1500 g for 60 s, take the supernatant and filter it through a 0.2 - μm sterile filter, and adjust the concentration of Platycladus orientalis extract calculated as quercetin in the mother liquor of Platycladus orientalis extract to 8000 μmol / L by adjusting the amount of absolute ethanol used to obtain it;

[0032] (2) Weigh 1 part of glycine, 1 part of glutamine, 3.2 parts of pentanediol, 0.5 part of arginine hydrochloride, and 0.1 part of sodium hyaluronate in sequence according to the mass ratio, then add purified water to make up the volume, stir for 50 min until completely dissolved, measure the pH value, and filter through a 0.2 μm sterile filter to obtain a buffer system;

[0033] (3) Dilute the mother liquor of Platycladus orientalis extract with purified water and mix well; add the sodium DNA into the aqueous solution of the diluted mother liquor of Platycladus orientalis extract, gently shake and mix for 30 min; then add the buffer system, gently shake and mix for 15 min, and adjust the concentration of sodium DNA in the obtained anti - hair - loss composition to 62.5 nmol / L, the concentration of the mother liquor of Platycladus orientalis extract to 80 μmol / L, and the mass concentration of glycine to 1% by adjusting the amounts of purified water and buffer system.

[0034] (4) Wash the packaging materials with purified water in advance, drain the water, dry them in an oven at 70 °C for 30 min, take them out and cool them completely for standby. Use a disposable pipette to dispense samples according to the filling volume in a clean bench. After sample dispensing, store them in a low - temperature refrigerator at 4 °C.

[0035] Example Two:

[0036] It is implemented according to the same conditions and steps as in Example One, the difference is that: in step (1), the production raw material formula measures raw materials according to the molar ratio: 0.125 part of sodium DNA calculated as deoxyribonucleic acid sodium salt, 80 parts of the mother liquor of Platycladus orientalis extract calculated as quercetin; in step (3), by adjusting the amounts of purified water and buffer system, the concentration of sodium DNA in the obtained anti - hair - loss composition is adjusted to 125 nmol / L, the concentration of the mother liquor of Platycladus orientalis extract is 80 μmol / L, and the mass concentration of glycine is 1%.

[0037] Example Three:

[0038] It is implemented according to the same conditions and steps as in Example One, the difference is that: in step (1), the production raw material formula measures raw materials according to the molar ratio: 0.25 part of sodium DNA calculated as deoxyribonucleic acid sodium salt, 80 parts of the mother liquor of Platycladus orientalis extract calculated as quercetin; in step (3), by adjusting the amounts of purified water and buffer system, the concentration of sodium DNA in the obtained anti - hair - loss composition is adjusted to 250 nmol / L, the concentration of the mother liquor of Platycladus orientalis extract is 80 μmol / L, and the mass concentration of glycine is 1%.

[0039] Example Four:

[0040] It was implemented under the same conditions and steps as in Example 1, with the differences being: in step (1), the production raw material formula measured the raw materials by molar ratio: 0.50 part of DNA sodium calculated as sodium deoxyribonucleate, and 80 parts of the mother liquor of Platycladus orientalis extract calculated as quercetin; in step (3), the concentration of DNA sodium in the obtained anti-hair loss composition was adjusted to 500 nmol / L by adjusting the amounts of purified water and buffer system, the concentration of the mother liquor of Platycladus orientalis extract was 80 μmol / L, and the mass concentration of glycine was 1%.

[0041] Example 5:

[0042] It was implemented under the same conditions and steps as in Example 1, with the difference being: in step (1), DNA sodium and the Platycladus orientalis extract were made into a mixed mother liquor. The preparation method: dissolve the Platycladus orientalis extract (C 槲皮素 is 3.2%) with purified water, and then mix it with the DNA sodium solution pre-dissolved in the buffer. The buffer is 40 mmol / L disodium hydrogen phosphate and 2.4 mmol / L sodium dihydrogen phosphate.

[0043] Comparative Example 1:

[0044] This comparative example was a control experiment for Example 2, and was implemented under the same steps and conditions as in Example 2, with the only difference being: DNA sodium was not used. The specific implementation method is as follows:

[0045] (1) Preparation of the mother liquor of Platycladus orientalis extract: Dissolve the Platycladus orientalis extract (C 槲皮素 is 3.2%) with absolute ethanol for 40 min, centrifuge at 1500 g for 60 s, take the supernatant and filter it through a 0.2 μm sterilizing filter, and adjust the concentration of the Platycladus orientalis extract calculated as quercetin in the mother liquor of Platycladus orientalis extract to 8000 μmol / L by adjusting the amount of absolute ethanol;

[0046] (2) Weigh 1 part of glycine, 1 part of glutamine, 3.2 parts of pentylene glycol, 0.5 part of arginine hydrochloride, and 0.1 part of sodium hyaluronate in sequence according to the mass ratio, add purified water to make up the volume, stir for 50 min until completely dissolved, detect the pH value, and filter through a 0.2 μm sterilizing filter to obtain the buffer system;

[0047] (3) Dilute the mother liquor of Platycladus orientalis extract with purified water and mix well; then gently shake and mix for 30 min; then add the buffer system, gently shake and mix for 15 minutes, and adjust the concentration of the mother liquor of Platycladus orientalis extract in the obtained anti-hair loss composition to 80 μmol / L by adjusting the amounts of purified water and buffer system, and the mass concentration of glycine is 1%.

[0048] (4) Wash the packaging materials with purified water in advance, drain the water, dry them in an oven at 70 °C for 30 minutes, take them out and let them cool down fully for standby. Use a disposable pipette to dispense the samples in a clean bench according to the filling volume. After sample dispensing, store them in a low-temperature refrigerator at 4 °C.

[0049] The concentration of the mother liquor of Platycladus orientalis extract in the obtained anti-hair loss composition is 80 μmol / L, and the mass concentration of glycine is 1%.

[0050] Comparative Example 2:

[0051] This comparative example is a control experiment of Example 2, which is carried out according to the same steps and conditions as Example 2, and the difference is only that: the mother liquor of Platycladus orientalis extract is not used. The specific implementation method is as follows:

[0052] (1) Weigh 1 part of glycine, 1 part of glutamine, 3.2 parts of 1,2-pentanediol, 0.5 part of arginine hydrochloride, and 0.1 part of sodium hyaluronate in sequence according to the mass ratio, add purified water to make up the volume, stir for 50 min until completely dissolved, detect the pH value, and filter through a 0.2 μm sterile filter to obtain a buffer system;

[0053] (2) Add sodium DNA to purified water and gently shake and mix for 30 min; then add the above buffer system, gently shake and mix for 15 minutes, and adjust the concentration of sodium DNA in the obtained anti-hair loss composition to 125 nmol / L and the mass concentration of glycine to 1% by adjusting the amounts of purified water and buffer system.

[0054] (3) Wash the packaging materials with purified water in advance, drain the water, dry them in an oven at 70 °C for 30 minutes, take them out and let them cool down fully for standby. Use a disposable pipette to dispense the samples in a clean bench according to the filling volume. After sample dispensing, store them in a low-temperature refrigerator at 4 °C.

[0055] Animal experiment:

[0056] The anti-hair loss compositions obtained in Example 1, Example 2, Example 3, Example 4, Comparative Example 1, and Comparative Example 2 above are respectively denoted as: treatment groups of drugs A, B, C, D, E, and F, and the following method is used to verify the anti-hair loss effect in animal experiments:

[0057] 1. Modeling method

[0058] 1.1. Hair removal

[0059] After anesthesia with isoflurane, at 0.5 cm proximal to the distal end of the mouse tail, use a small pet hair clipper to cut short the hair in a 2 cm × 3 cm area (the long axis is parallel to the spine) on the back of the mouse, then apply hair removal cream, and gently wipe off the hair removal cream with a wet cotton ball after about 5 min.

[0060] 1.2. Model establishment

[0061] On the day after hair removal, 200 μL of 0.5% (w / v) testosterone solution was applied to the back of each mouse and applied continuously for 21 days.

[0062] 2. Experimental design

[0063] Group design: 9 groups, normal control group, model control group, drug A, B, C, D, E, F treatment groups and positive control group;

[0064] Number of animals: 8 animals / group;

[0065] Sex ratio: all male;

[0066] Grouping method: 72 mice were randomly assigned to each group.

[0067] Specific grouping information is shown in Table 1:

[0068] Table 1 Grouping and drug administration information table

[0069]

[0070] 2.1. Drug administration information

[0071] Drug administration volume: 0.2 mL / animal;

[0072] Drug administration site: back skin;

[0073] Reason for selection: consistent with the intended clinical drug administration route;

[0074] Drug administration method: apply the drug by smearing on the experimental area of the back of the mouse;

[0075] Drug administration frequency and cycle: once a day, continuously applied for 21 days;

[0076] Modeling period / recovery period: 21 days;

[0077] The day of drug administration was defined as the first day of the experiment (day1, D1).

[0078] 2.2. Hair growth scoring

[0079] Scoring time: take pictures and score on the day of drug administration (D1), D10, 13, and D22;

[0080] Scoring method: Anesthetize the mouse slightly with isoflurane. The operator observes the hair coverage of the back experimental area of the mouse, takes pictures and uses Image J to measure the hair growth area for scoring. The scoring criteria are shown in Table 2:

[0081] Table 2 Hair growth scoring criteria

[0082]

[0083] 3. Gross anatomy and histopathological examination

[0084] 3.1. Dissection Time

[0085] 24 h after the last administration.

[0086] 3.2. Dissected Animals

[0087] All surviving experimental animals planned for measurement.

[0088] 3.3. Anesthesia and Euthanasia Methods

[0089] Anesthetize by intraperitoneal injection of ketamine & sumianxin II (100 mg / kg & 10 mg / kg). After mixing ketamine and sumianxin II, dilute 10 times with sterile injection water. After anesthesia, euthanize by exsanguination from the abdominal aorta.

[0090] 3.4. Tissue Sampling and Fixation

[0091] Take 2×3 cm of back skin 2 , put it into a specimen bottle and fix it in 10% neutral formalin fixative for 72 h, embed it in paraffin, section it, and use it for HE staining.

[0092] 3.5. Histopathological Examination

[0093] Randomly select 30 hair follicles in the longitudinal section of each experimental animal for counting the growing and resting hair follicles. After calculating the number of hair follicles in each period for each group, perform statistical analysis. If the number of hair follicles in the longitudinal section is less than 30, calculate according to the actual number of hair follicles.

[0094] 4. Statistical Analysis

[0095] Measurement indicators are expressed as mean ± standard deviation. When the sample size is less than 3, the data of this group are not included in the statistical comparison.

[0096] Except for the counting indexes of growing follicles and telogen follicles in the table, other animal experiment data are expressed as Mean±SD, and the experimental data in the pictures are described as Mean±SEM. Shapiro-Wilk normality test and homogeneity of variance test were performed on the data. One-Way ANOVA was used for the comparison among multiple groups that met the normality and homogeneity of variance, and LSD method of analysis of variance was used for the comparison between groups; if the variance was heterogeneous, Tamhane’s T2 method was used for analysis; if it did not conform to the normal distribution, Kruskal-Wallis H test (K-W method) was used for the comparison among multiple groups, and Dunn’s nonparametric multiple comparison test was combined. Chi-square test was used for the counting indexes of growing follicles and telogen follicles. Multiple chi-square tests were used to compare the categorical variable rates or constituent ratios of multiple independent samples. The data were usually organized in the form of a row×column table, and the expected frequency and chi-square statistic were calculated to judge whether there were significant differences among groups. When the chi-square test showed differences overall, Bonferroni correction was used for multiple comparisons to determine the specific differences between groups. P<0.05 was considered statistically significant, and all statistical analyses were completed using SPSS 27.

[0097] 5. Results

[0098] In this experiment, an androgenetic alopecia model of C57BL / 6 mice was induced by applying testosterone solution on the back. After modeling every day, the test drug was applied for treatment once a day for 21 consecutive days. On the administration day (D1), D10, D13, and D22, the experimenters observed and photographed the hair growth on the backs of the mice, and used Image J to measure the hair coverage of the experimental area, measure the hair growth area, calculate the hair coverage rate by "hair growth area÷experimental area area" (the results are shown in Table 3), and score according to Table 2; and 24 hours after the last administration (D22), the back skin of the mice was taken for HE staining to count the growing and telogen follicles. And according to the statistical analysis results of each index, the therapeutic effect of the test drug on the androgenetic alopecia model was evaluated. The results showed that:

[0099] (1) Under the conditions set in this experiment, the model control group animals showed obvious disease characteristics of androgenetic alopecia compared with the normal control group, including a decrease in hair coverage rate and a decrease in hair growth score in the model control group animals; a decrease in the number of growing follicles and an increase in the number of telogen follicles, indicating that the model was successfully established.

[0100] (2) Compared with the model control group, on the 22nd day of drug administration, the hair coverage rate and hair growth score of the animals in the treatment groups of drugs A, B, C, D, E, F and the positive control group showed an increasing trend. Among them, compared with the model control group, the hair coverage rate and hair growth score of the treatment groups of drugs A, B, C, D and the positive control group had highly significant differences (P<0.001).

[0101] (3) Through the comparison of the hair coverage rate data of the treatment groups of drug B, drug E and drug F (see Table 3), it can be seen that when sodium deoxyribonucleate or the mother liquor of Platycladus orientalis extract was used alone, the hair coverage rate of D13 was 2.92% and 3.08% respectively, while when the two were used in combination, the hair coverage rate of D13 was as high as 15.46%; it can be seen that when sodium deoxyribonucleate and the mother liquor of Platycladus orientalis extract were used in combination, they had an obvious synergistic effect in improving the hair growth rate.

[0102] (4) Compared with the model control group, the number of growing-phase hair follicles in each drug administration group increased to varying degrees, and the number of resting-phase hair follicles decreased to varying degrees. Among them, the increase in the number of growing-phase hair follicles and the decrease in the number of resting-phase hair follicles in the treatment groups of drugs A, B, C, D, E and the positive control group were more significant, and the differences were all statistically significant (P<0.05).

[0103] (5) Compared with the treatment groups of drugs E and F respectively, on the 22nd day of drug administration, the hair coverage rate and hair growth score of the treatment groups of drugs A, B, C, D increased significantly, and the differences were highly statistically significant (P<0.01).

[0104] In summary, under the conditions set in this experiment, an animal model that conforms to the characteristics of androgenetic alopecia was successfully established. The test drugs A, B, C, D, E, F and the positive control drug 5% minoxidil liniment all had a certain therapeutic effect on the androgenetic alopecia model and could improve the hair growth situation and the histopathological characteristics of hair follicles. Among them, the treatment group with the combination of sodium deoxyribonucleate and Platycladus orientalis extract (the treatment groups of test drugs A, B, C, D) had a significantly better effect on improving hair growth than sodium deoxyribonucleate alone (the treatment group of test drug E) or Platycladus orientalis extract alone (the treatment group of test drug F). Compared with the positive control group, the treatment group of drug B (125 nM sodium deoxyribonucleate + 80 μM Platycladus orientalis extract) and the treatment group of drug C (250 nM sodium deoxyribonucleate + 80 μM Platycladus orientalis extract) had particularly significant effects and showed similar or better therapeutic effects on multiple evaluation indicators.

[0105] Table 3 Hair coverage rate

[0106]

[0107] Note: In the table, those with the same marked letter indicate that the difference is not statistically significant, while those with different marked letters indicate that the difference is statistically significant (P < 0.05); compared with the normal control group, *P < 0.05, **P < 0.01, ***P < 0.001; compared with the model control group, # P < 0.05, ## P < 0.01, ### P < 0.001.

[0108] Table 4 Hair Growth Scoring Table

[0109]

[0110] Note: In the table, those with the same marked letter indicate that the difference is not statistically significant, while those with different marked letters indicate that the difference is statistically significant (P < 0.05); compared with the normal control group, *P < 0.05, **P < 0.01, ***P < 0.001; compared with the model control group, # P < 0.05, ## P < 0.01, ### P < 0.001.

[0111] Table 5 Number of Hair Follicles in Anagen and Telogen

[0112]

[0113] Note: Compared with the normal control group, *P < 0.05 in the model group; compared with the model control group, # P < 0.05.

[0114] Subject Experiment:

[0115] Drugs A, B, C, and D were respectively provided to four groups of alopecia patients, namely A, B, C, and D, for continuous use for 28 days. The usage method was to suck 0.5 - 1 ml of the drug with a dropper, drop it on the scalp care area, massage with the finger pulp until absorbed, without rinsing, once in the morning and once in the evening. The grouping and curative effects are shown in Table 6 and Figures 5 to 7 as follows.

[0116] Table 6 Subject Test Results Table

[0117]

[0118]

[0119]

Claims

1. A method for preparing an anti-hair loss composition, characterized in that: The production raw material formula includes a sodium DNA-platycladus orientalis leaf extract composite solution and a buffer system; the sodium DNA-platycladus orientalis leaf extract composite solution includes the following components in molar proportions: 0.06 to 0.5 parts of sodium DNA calculated as deoxyribonucleic acid sodium salt and 80 parts of the platycladus orientalis leaf extract mother liquor calculated as quercetin.

2. The method for preparing the anti-hair loss composition according to claim 1, characterized in that: The Platycladus orientalis leaf extract mother solution is obtained by dissolving the Platycladus orientalis leaf extract in ethanol.

3. The method for preparing the anti-hair loss composition according to claim 2, characterized in that: The concentration of the Platycladus orientalis leaf extract in the Platycladus orientalis leaf extract mother solution is 7000-9000 μmol / L in terms of quercetin.

4. The method for preparing the anti-hair loss composition according to any one of claims 1 to 3, characterized in that: The raw materials for preparing the buffer system include the following components in the following mass proportions: 1 part of glycine, 0.5-1.5 parts of glutamine, 2-4 parts of pentanediol, 0.3-0.8 parts of arginine hydrochloride, and 0.05-0.2 parts of sodium hyaluronate.

5. The method for preparing the anti-hair loss composition according to claim 4, characterized in that: The concentration of sodium DNA in the anti-hair loss composition is 60-500 nmol / L in terms of deoxyribonucleic acid sodium salt.

6. The method for preparing the anti-hair loss composition according to claim 2 or 3, characterized in that: The mother liquor of Platycladus orientalis leaf extract is prepared as follows: anhydrous ethanol is used to dissolve the Platycladus orientalis leaf extract, and the mother liquor is obtained after centrifugation at 1200-1800g for more than 30s and sterilization filtration is performed to obtain the mother liquor.

7. The method for preparing the anti-hair loss composition according to any one of claims 1 to 3, 5 or 6, characterized in that: The steps include: S1, measuring the raw materials according to the production raw material formula; S2, diluting the Platycladus orientalis leaf extract mother solution with purified water; adding the sodium DNA into the diluted aqueous solution of the Platycladus orientalis leaf extract mother solution and mixing; then adding the buffer system according to the concentration set by the process and mixing.

8. An anti-hair loss composition obtained by the method for preparing an anti-hair loss composition according to any one of claims 1 to 7.

9. An external preparation for preventing hair loss, characterized in that: The components of the external preparation for preventing hair loss include the anti-hair loss composition according to claim 8.

10. The external preparation for preventing hair loss according to claim 9, characterized in that: The external preparation for preventing hair loss is an anti-hair loss cosmetic, an anti-hair loss external spray or an anti-hair loss external ointment.

Images